Boston Scientific Corp. (BSX) reported positive results from two trials evaluating new, drug-eluting stent technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element Stent System were presented at the annual EuroPCR Scientific Program in Paris.
The NG PROMUS Clinical Trial evaluated the clinical and angiographic outcomes for the Promus PREMIER Stent System at 30 days. As per the trial results, the Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis. The rate of technical success, the primary endpoint of the trial, was high at 99.2 percent. The clinical results of the SYNERGY Stent in EVOLVE were impressive with respect to safety and efficacy.
The Promus PREMIER and SYNERGY Stents have CE Mark approval. In the United States and Japan, they are limited to investigational use only.
For comments and feedback: editorial@rttnews.com